Proton Transport Inhibitors as Potentially Selective Anticancer Drugs

• Published in: Anticancer research 2009-06, Vol.29 (6), p.2127-2136
• Main Authors: HARGUINDEY, Salvador, ARRANT, Jose Luis, WAHL, Miriam L, ORIVE, Gorka, RESHKIN, Stephan J
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Humans; Medical sciences; Neoplasms - drug therapy; Proton Pump Inhibitors; Tumors; Vacuolar Proton-Translocating ATPases - antagonists & inhibitors
• ISSN: 0250-7005; 1791-7530

Different research groups have recently described a proton [H + ]-related mechanism underlying the initiation and progression of the neoplastic process in which all cancer cells and tissues, regardless of their origin and genetic background, have a pivotal energetic and homeostatic disturbance of their metabolism that is completely different from all normal tissues: an aberrant regulation of hydrogen ion dynamics leading to a reversal of the pH gradient in cancer cells and tissues (∆pH i to ∆pH e ) as compared to normal tissue pH gradients. This basic specific abnormality of the relationship between the intracellular and the extracellular proton dynamics, a phenomenon that is increasingly considered to be one of the most differential hallmarks of cancer, has led to the formation of a unifying thermodynamic view of cancer research that embraces cancer fields from etiopathogenesis, cancer cell metabolism, multiple drug resistance (MDR), neovascularization and the metastatatic process to selective apoptosis, cancer chemotherapy and even the spontaneous regression of cancer (SRC). This reversed proton gradient is driven by a series of proton export mechanisms that underlie the initiation and progression of the neoplastic process. This means that therapeutic targeting of the transporters that are active in cancer cells could be selective for malignancy and is likely to open new pathways towards the development of more effective and less toxic therapeutic measures for all malignant diseases. Here we review the transporters involved in driving the reversed proton gradient and their specific inhibitors.